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Abstract NeuroinXammation, initiated by cerebral infec-
tion, is increasingly postulated as an aetiological factor in
neurodegenerative diseases such as Alzheimer’s disease
(AD). We investigated whether Chlamydia pneumoniae
(Cpn) infection results in extracellular aggregation of amy-
loid beta (A) in BALB/c mice. At 1 week post intranasal
infection (p.i.), Cpn DNA was detected predominantly in
the olfactory bulbs by PCR, whereas brains at 1 and
3 months p.i. were Cpn negative. At 1 and 3 months p.i.,
extracellular A immunoreactivity was detected in the
brain of Cpn-infected mice but also in the brain of mock-
infected mice and mice that were neither Cpn infected nor
mock infected. However, these extracellular A aggre-
gates showed morphological diVerences compared to
extracellular A aggregates detected in the brain of transgenic
APP751SL/PS1M146L mice. These data do not unequivocally
support the hypothesis that Cpn infection induces the for-
mation of AD-like A plaques in the brain of BALB/c
mice, as suggested before. However, future studies are
required to resolve these diVerences and to investigate
whether Cpn is indeed an etiological factor in AD patho-
genesis.
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Introduction
The most common cause of dementia is Alzheimer’s dis-
ease (AD), which manifests in a familial and a sporadic
form. The neuropathology in both conditions is character-
ized by neuritic or senile plaques, consisting mainly of
amyloid beta protein (A) and neuroWbrillary tangles with
hyperphosphorylated tau protein as its key components.
Mutations in the amyloid precursor protein (APP), preseni-
lin-1 (PS-1) or -2 (PS-2) genes have been associated with
the familial form of AD [27]. However, the most common
type of this disease, sporadic AD, is not due to these muta-
tions, and although risk factors have been identiWed, the
initiating trigger is still unknown [18]. The potential
importance of infections in the development of sporadic
AD has been recently recognized [1, 21, 31]. SpeciWcally,
not only various viruses like the human immunodeWciency
virus, herpes simplex virus and cytomegalovirus but also
bacteria like Borrelia burgdorferi, have been linked to the
process of neurodegeneration [6, 12, 13,  17, 20]. Some
data also suggest that Chlamydia pneumoniae (Cpn)
should be added to the list of pathogens possibly involved
in the pathogenesis of AD. Cpn is a widespread, obligatory
intracellular pathogen, often causing acute respiratory
infections including pneumonia, sinusitis and bronchitis
[10, 11, 15]. This microorganism has also been implicated
in a variety of severe, chronic diseases including some
E. Boelen (&) · F. R. M. Stassen · C. A. Bruggeman
Department of Medical Microbiology, 
Cardiovascular Research Institute Maastricht (CARIM), 
Maastricht University, PO Box 616, 6200 MD Maastricht, 
The Netherlands
e-mail: Eboe@lmib.azm.nl
E. Boelen · M. A. M. Lemmens · H. P. J. Steinbusch · 
C. Schmitz · H. W. M. Steinbusch
Department of Neuroscience, Maastricht University, 
Maastricht, The Netherlands
A. J. A. M. van der Ven
Department of General Internal Medicine, 
University Medical Centre St Radboud, 
Nijmegen, The Netherlands256 Acta Neuropathol (2007) 114:255–261
123
disorders of the central nervous system [7, 14, 30, 32]. In
an initial study, Balin et al. demonstrated the presence of
Cpn in brains of 17 out of 19 patients with sporadic AD,
using a variety of techniques, including PCR, electron
microscopy and immunohistochemistry, while the patho-
gen could only be demonstrated in 1 out of 19 controls [2].
The presence of Cpn was demonstrated in various cell
types like microglia, astrocytes, perivascular macrophages
and monocytes, and predominantly in brain areas linked
with AD pathology. Recently, these observations were
conWrmed [8]. On the contrary, others were unable to
detect Cpn in AD patient tissues [9, 22, 23, 28]. The only
animal study so far supporting a role for this pathogen in
AD demonstrated an AD-like pathology in the brain of
BALB/c mice post Cpn infection [19]. Three-month-old
mice were inoculated intranasally with Cpn and the
authors claimed that this resulted in the deposition of A
in the brain up to 3 months post infection with increasing
pathology as the infection progressed. Based on these
results, it was concluded that in naïve BALB/c mice, AD-
like pathology could be induced by Cpn infection. In spite
of these results, doubts remain concerning the amyloid-
like plaques as being only unrelated elevations in amyloid
[24]. Because of the possible implications of this study and
the need for conWrmation, it was our aim to repeat these
experiments under quite corresponding conditions. More-
over, we compared our Wndings with the pathology found
in a transgenic mouse model of AD.
Materials and methods
Chlamydia pneumoniae
The Cpn strain, TWAR 2043 (ATCC) was cultured and
continuously propagated on Hep2 cells as previously
described [25]. Bacterial titres were determined by titration
in Hep2 cells [7] and staining with a monoclonal Chla-
mydia LPS-speciWc antibody followed by a FITC-conju-
gated secondary antibody (RR-402; DAKO, Glostrup,
Denmark). Titres were expressed as the number of inclu-
sion forming units (IFU) per ml.
Animals and infection protocol
A total of 43 female, speciWc pathogen-free inbred BALB/c
mice were obtained from Charles River (Someren, The
Netherlands). Animals were kept under standard housing
and care conditions at the Central Animal Facilities of
Maastricht University (Maastricht, The Netherlands). All
experimental procedures were approved by the Ethical
Committee for the Use of Experimental Animals of Maas-
tricht University.
At 3 months of age n = 24 mice were inoculated intrana-
sally with 107 IFU Cpn in 10 l (5 l per nostril), and were
analyzed at 1 week, 1 month or 3 months p.i., respectively,
as shown in Table 1. Pilot experiments revealed that this
dosage ensures both survival of the mice and optimal dis-
semination throughout the body. Another n = 15 mice were
mock infected with a sucrose-phosphate-glucose solution
(SPG, solution for storage of Cpn) at 3 months of age and
were also analyzed at 1 week, 1 month or 3 months after
mock infection, as shown in Table 1. In addition, two mice,
which did not receive any treatment, were investigated at
4 months of age, as well as two mice at 6 months of age
(Table 1).
In addition, a 17-month-old transgenic mouse expressing
human mutant APP751 (carrying the Swedish and London
mutations KM670/671NL and V717I, under the Thy1 pro-
moter) and human mutant presenilin-1 (PS-1 M146L, under
the HMG promoter) was used (APP751SL/PS1M146L mouse;
for a detailed description see refs [4] and [24]) (Table 1).
This APP751SL/PS1M146L mouse was bred on a CBA
(12.5%) £ C57Bl6 (87.5%) background.
Detection of Cpn DNA in brain tissue with real-time PCR
As shown in Table 1, 15 mice were used to detect Cpn
DNA in brain tissue with real-time PCR at diVerent time
points after infection with Cpn or mock infection. To this
end the animals received a weight-adjusted dose of pento-
barbital (Nembutal; SanoW Sante B.V., Maassluis, The
Netherlands) and were then perfused with sterile phosphate
buVered saline. Brains were removed quickly and dissected
into Wve diVerent regions, i.e., olfactory bulbs, cerebellum,
Table 1 Numbers of animals per group investigated in the present study
Cpn Chlamydia pneumoniae, IHC immunohistochemistry, 1w/1m/3m, analysis 1 week (or 1 month or 3 months, respectively) after Cpn infection
or mock infection at 3 months of age. M4/M6/M17, 4, 6 or 17 months of age, respectively
Mouse strain; analysis Infection with Cpn Mock infection No treatment
1w 1m 3m 1w 1m 3m M4 M6 M17
BALB/c; PCR 4 4 4 1 1 1 – – –
BALB/c; IHC – 6 6 – 6 6 2 2 –
APP751SL/PS1M146L –––– – – – – 1Acta Neuropathol (2007) 114:255–261 257
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hippocampus, subventricular zone and neocortex. The iso-
lated regions were snap-frozen in liquid nitrogen and stored
at ¡80°C until further processing.
DNA was isolated from brain material using methods
previously described [5]. The Nanodrop® ND-1000, a full-
spectrum spectrophotometer (220–750 nm) was used to
calculate the DNA content of each sample. Finally, the Cpn
DNA copy number/g DNA in the collected brains was
determined by real-time PCR (ABI Prism 7000; Applied
Biosystems, Foster City, CA, USA) using the following
primers and probe; forward (5TCCGCATTGCTCAGCC3),
reverse (5AAACA ATTTGCATGAAGTCTGAGAA3) and
probe (5-FAM-TAAACTTAACTGCATGGAACCCTTC
TTTACTAGG3-T AMRA) as described previously [5, 29].
All PCR runs were performed in duplo. Mean Cpn DNA
copy numbers/g brain DNA of three independent experi-
ments (§SEM) was calculated. Then, comparisons between
all groups of mice, analyzed for the presence of Cpn DNA
in brain tissue, were performed with three-way ANOVA
with Treatment (Cpn infection or mock infection), Time-
point of analysis (1 week, 1 month or 3 months p.i.) and
Brain region (olfactory bulbs, cerebellum, hippocampus,
subventricular zone or neocortex) as Wxed factors. P values
smaller than 0.05 were considered statistically signiWcant.
Calculations were performed with SPSS v. 12.0.1 for
Windows (SPSS, Chicago, IL, USA).
Detection of Aß aggregates in brain tissue 
with immunohistochemistry
As also shown in Table 1, n = 29 mice were used to detect A
aggregates in brain tissue with immunohistochemistry at
diVerent time points after infection with Cpn, mock infection
or without any treatment, respectively. To this end, the ani-
mals received a weight-adjusted dose of pentobarbital (Nem-
butal; SanoW Sante B.V., Maassluis, The Netherlands) and
were then subjected to intracardial perfusion Wxation, as previ-
ously described [26]. In case of the APP751SL/PS1M146L
mouse, anaesthesia was performed with chloral hydrate (10%
aqueous solution, 0.005 ml/g body weight, i.p.). Brains were
removed rapidly and post-Wxed for 2 h at 4°C in the same
Wxative, omitting the glutaraldehyde. In case of the
APP751SL/PS1M146L mouse, the brains were halved in the
midsagittal line. Brain tissues were then cryoprotected by
immersion in 30% sucrose in Tris-buVered saline at 4°C over-
night. Afterwards, brains (or brain halves, respectively) were
quickly frozen and stored at ¡80°C until further processing.
For immunohistochemical analysis, the entire brains (or
the right brain half in case of the APP751SL/PS1M146L
mouse) were cut into entire series of 30-m-thick frontal
sections on a cryostat (Leica CM 3050 S; Leica, Nussloch,
Germany). After cutting, sections were again stored at
¡80°C until further processing.
Immunohistochemical detection of A (as well as of glial
Wbrillary acidic protein) was performed with standard immu-
noXuorescence procedures using a Wrst layer, consisting of a
combination of mouse anti-human amyloid 17–24 (4G8
clone; 1:1,200 in TBS-T; Sigma-Aldrich, St Louis, USA) [3,
16, 33] and polyclonal rabbit anti-mouse GFAP (1:1,600 in
TBS-T; DAKO, Glostrup, Denmark). The corresponding
secondary antibodies were donkey anti-mouse Alexa 488
(1:100 in TBS-T; Molecular Probes) and donkey anti-rabbit
Alexa 594 (1:100 in TBS-T; Molecular Probes). Finally,
counterstaining was performed with Hoechst (1:500 in TBS;
Sigma, St Louis, MO, USA) and sections were mounted on
gelatine-coated glasses. As a negative control, sections were
only incubated with the secondary antibodies.
Detection of extracellular Aß aggregates in brain tissue 
with thioXavin-S
For the detection of extracellular, Wbrillary A, a standard
thioXavin-S (Sigma) staining was performed. Finally, the
sections were counterstained with Hoechst and mounted as
described above.
Microscopy and photography
Microscopic inspection of sections was performed with a
MBF Bioscience Stereo Investigator Confocal Spinning
Disk (SI-SD) system (MBF Bioscience; Williston, VT,
USA), consisting of a modiWed Olympus BX51 Xuores-
cence microscope (Olympus, Tokyo, Japan) with UPlan-
SApo objectives 10 £ (N.A. = 0.4), 40 £ (N.A = 0.9) and
100 £ (oil; N.A = 1.4); Olympus, customized spinning disk
unit (DSU; Olympus), computer-controlled excitation and
emission Wlter wheels (Olympus), three-axis high-accuracy
computer-controlled stepping motor specimen stage (4 £ 4
Grid Encoded Stage; Ludl Electronic Products, Hawthorne,
NY, USA), linear z-axis position encoder (Ludl), ultra-high
sensitivity monochrome electron multiplier CCD camera
(1,000 £ 1,000 pixels, C9100-02; Hamamatsu Photonics,
Hamamatsu City, Japan) and controlling software (MBF
Bioscience). In case of sections processed for the detection
of Aß and GFAP, digital RGB image stacks showing the
same microscopic Weld in 50 consecutive focal planes with a
distance of 0.5 m between the focal planes were generated
with the 40£ objective. In the case of sections stained with
thioXavin-S, digital image stacks showing the same micro-
scopic Weld at 150 consecutive RGB focal planes with a
distance of 0.2 m between the focal planes were generated
with the 100£ objective. From these image stacks three-
dimensional reconstructions (maximum intensity projec-
tions) were produced with Imaris software (Version 4.0;
Bitplane, Zurich, Switzerland). In addition, low-power
photomicrographs (10£) were taken from sections stained258 Acta Neuropathol (2007) 114:255–261
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with thioXavin-S. Final Wgures were constructed using
Corel Photo-Paint v.11 and Corel Draw v.11 (Corel, Ottawa,
Canada). Only minor adjustments of contrast and bright-
ness were made, without altering the appearance of the
original materials. No deconvolution was performed on
images obtained by confocal microscopy.
Results
Presence of Cpn in the brain of BALB/c mice infected 
with Cpn
At 1 week p.i., the mean Cpn DNA copy number per g
DNA was 310.97 § 61.6 (mean § SEM) in the olfactory
bulbs, 2.6 § 0.8 in the cerebellum and 7.9 § 0.8 in the hip-
pocampus, while no Cpn DNA was detected in the subven-
tricular zone and the neocortex (Table 2). No Cpn DNA
was detected in any brain region of the Cpn infected mice at
1 and 3 months p.i.. Furthermore, Cpn DNA was not
detected in the brain of mock-infected BALB/c mice at any
time point. Statistical analysis revealed signiWcant diVer-
ences among the groups of mice with respect to Treatment
(T) (P = 0.024), Time point of analysis (Tpoa) (P = 0.008)
and Brain region (Br) (P = 0.002), as well as with respect to
the combinations T–Tpoa (P = 0.008), T–Br (P = 0.002),
Tpoa–Br (P < 0.001) and T–Tpoa–Br (P < 0.001).
Detection of A and GFAP in the brain of BALB/c 
and APP751SL/PS1M146L mice
Amyloid beta immunoreactivity was found in the brains of
all mice, i.e. in Cpn-infected BALB/c mice at both 1 and
3 months p.i. (Fig. 1a), mock-infected BALB/c mice at both
1 and 3 months after mock infection (Fig. 1b), not inocu-
lated BALB/c mice (Fig. 1c) and in APP751SL/PS1M146L
mice (Fig. 1d). However, A-immunopositive aggregates
were found only occasionally in the brains of the BALB/c
mice (on average one to two aggregates per section without
a preference for a certain brain region), whereas they were
found abundantly in hippocampus and neocortex of
APP751SL/PS1M146L mice (see also Fig.2H in [24]). Fur-
thermore, there were several qualitative diVerences between
the APP751SL/PS1M146L and the BALB/c mice. First, in the
brain of APP751SL/PS1M146L mice, the materials immuno-
positive for A formed a dense core, devoid of Hoechst-pos-
itive structures (i.e. cell nuclei). In contrast, the materials
immunopositive for A in the brain of BALB/c mice did not
present with a dense core, and Hoechst-positive structures
were scattered within these materials. Second, the astrocytic
reaction in the brain of APP751SL/PS1M146L mice, surround-
ing the A-immunopositive materials, was much stronger
than in the brain of BALB/c mice (arrowheads in Fig. 1a–d).
Third, in the brain of APP751SL/PS1M146L mice, cells with
intracellular deposits of A were found (asterisk in Fig. 1d),
which was not observed in the brain of BALB/c mice, irre-
spective of treatment.
Detection of thioXavin-S-positive structures in the brain
of APP751SL/PS1M146L but not in the brain 
of BALB/c mice
In the brain of APP751SL/PS1M146L mice, extracellular thio-
Xavin-S-positive structures were found (Fig. 1e, f) as also
previously reported [4, 26], resembling Wbrillary A depos-
its. Such extracellular thioXavin-S-positive structures were
not found in the brain of BALB/c mice.
Discussion
The role of inXammatory factors, predominantly caused by
infections, in the initiation or acceleration of neurodegener-
ative diseases is increasingly recognized. Next to several
viruses [6, 12, 13, 17], the obligatory intracellular bacte-
rium Cpn has also been linked to a variety of neurodegener-
ative diseases such as AD. In 1998, the presence of this
pathogen was described in postmortem brains from patients
with AD [2]. That Cpn may contribute to neurodegenera-
tive processes was recently supported by data from our lab-
oratory, as we demonstrated that Cpn is able to infect
neurons, ultimately resulting in neuronal cell death in vitro
[5]. However, to the best of our knowledge only one exper-
imental in vivo study has been published so far supporting
a role for Cpn in AD [19]. In this study, naïve BALB/c
mice were inoculated intranasally with Cpn at an age of
3 months. Brains were recovered at 1–3 months p.i., reveal-
ing the presence of amyloid-like plaques and astrocyte
reactivity. Due to the possible impact of this study, it was
our goal to conWrm these data by repeating these experi-
ments. Focusing on our results of Cpn-inoculated mice at
3 months p.i., material immunopositive for A was indeed
Table 2 Detection of Cpn DNA in various brain regions (olfactory
bulbs, cerebellum, hippocampus, subventricular zone and neocortex)
with real-time PCR at 1 week, 1 month and 3 months post infection
Data were expressed as mean values of three independent experiments
§SEM
1 week p.i. 1 month p.i. 3 months p.i.
Olfactory bulbs 310.97 § 61.6 0 0
Cerebellum 2.6 § 0.8 0 0
Hippocampus 7.9 § 0.8 0 0
Subventricular 
zone
00 0
Neocortex 0 0 0Acta Neuropathol (2007) 114:255–261 259
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detected in the brain. Accordingly, at Wrst glance, our
results are in line with the study of Little et al. [19]. Com-
paring the morphological appearance of this material
immunopositive for A with corresponding material in the
brain of APP751SL/PS1M146L mice, however, some signiW-
cant and important diVerences were observed. First, one
characteristic of neuritic (AD) plaques is the presence of
Wlamentous, star-shaped aggregates of A  Wbrils with a
thioXavin-S-positive dense core. However, neither such
star-shaped aggregates of A Wbrils nor extracellular thio-
Xavin-S-positive structures were found in any of the brains
of Cpn infected or mock infected BALB/c mice, whereas
both lesions were abundant in the brain of APP751SL/
PS1M146L mice. Second, no damage was found in the tissue
surrounding the material immunopositive for A. Rather
Hoechst-positive structures (i.e. cell nuclei) could be
detected within the material immunopositive for A, a fea-
ture that was not seen in the brain of APP751SL/PS1M146L
mice. Finally, although astrocytes were found in the vicin-
ity of the material immunopositive for A in the brain of
Cpn infected or mock infected BALB/c mice, they were not
intimately associated with the A immunoreactivity, as
seen in the brain of APP751SL/PS1M146L mice. In summary,
except that A plaques were detected in most brains, our
data suggest that at 3 months after Cpn infection most char-
acteristic features of AD pathology could not be detected in
Fig. 1 Immunohistochemical detection of A ( green) and GFAP
(red) in 30 m-thick cryostat sections counterstained with Hoechst
(blue) from the brain of a 6-month-old Cpn-infected BALB/c mouse
3 months post infection (a), a 6-month-old mock infected BALB/c
mouse 3 months after mock infection (b), a 6-month-old BALB/c
mouse neither infected with Cpn nor mock infected (c) and a 17-
month-old APP751SL/PS1M146L transgenic mouse (d). Note that mate-
rial immunopositive for A was found in the brain of all mice (arrows).
However, there were diVerences between the APP751SL/PS1M146L
mouse and the BALB/c mice: (1) in the brain of the APP751SL/
PS1M146L mouse the material immunopositive for A formed a dense
core devoid of Hoechst-positive structures (i.e. cell nuclei). In contrast,
the material immunopositive for A in the brain of the BALB/c mice
did not present with a dense core, and Hoechst-positive structures were
scattered within it. (2) The astrocytic reaction in the brain of the
APP751SL/PS1M146L mouse surrounding the material immunopositive
for A was much stronger than in the brain of the BALB/c mice
(arrowheads). (3) In the brain of the APP751SL/PS1M146L mouse cells
with intracellular deposits of material immunopositive for Aß were
found (asterisk in d). This was not observed in the brain of the BALB/
c mice. Furthermore, extracellular thioXavin-S-positive structures in
the brain of the 17-month-old APP751SL/PS1M146L mouse are shown [e
(arrowheads) and f, resembling Wbrillary A deposits. Scale
bar =2 5m in a–d, 100 m in e and 10 m in f 260 Acta Neuropathol (2007) 114:255–261
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6-month-old naïve, non-transgenic BALB/c mice, whereas
these were prominent in the brain of the “control”
APP751SL/PS1M146L mice. It may still be argued that the
material immunopositive for A in the brain of the Cpn-
infected mice represented early precursors of neuritic
plaques. To our surprise, however, nearly identical patterns
of A immunoreactivity were detected in mock-infected
BALB/c mice as well as in BALB/c mice, neither Cpn
infected nor mock infected. This suggests that the observed
immunoreactivity for A in the brain of BALB/c mice does
not directly result from Cpn infection but might represent
unrelated elevations in amyloid. Positive staining for A in
the brain of mock-infected mice was also observed by Little
et al. [19], who found that the amyloid deposition load and
size were signiWcantly enhanced in Cpn-infected mice com-
pared to mock infected ones. As outlined above, this was
not found in the present study. Furthermore, Little et al.
also demonstrated the presence of a small subset of thioXa-
vin-S positive plaques, which were not found in our mice.
These discrepancies between the study by Little et al. [19]
and the present study could be due to the fact that Little
et al. [19] used a Cpn strain (C. pneumoniae, 96-41, iso-
lated from the postmortem brain of an AD patient) that was
rather diVerent from the Cpn strain used in the present
study (TWAR 2043, ATCC). Notably, Little et al. [19],
were able to detect Cpn in olfactory tissues of infected mice
up to 3 months p.i., by both light and electron microscopy.
In the present study, however, we were only able to detect
Cpn DNA in the olfactory bulb of infected BALB/c mice at
1 week p.i. but not at 1 or 3 months p.i., despite the use of a
more sensitive detection method (real-time PCR). As it is
well established that the clinical isolates of pathogens are
often more infectious than their laboratory counterparts,
this could partially explain the discrepancy between both
studies. Furthermore, it cannot be excluded that diVerences
in solutions used for mock infection (Hanks balanced salt
solution in the study by Little et al. [19] vs. SPG solution in
the present study) may have aVected the Wnal outcome. Yet,
in the present study, the immunosignal in mice that were
neither Cpn infected nor mock infected appeared somewhat
weaker than in the brain of the BALB/c mice that were
either Cpn- or mock-infected (a detailed quantitative analy-
sis was not performed). This suggests that intranasal appli-
cation of Cpn or other infectious agents may trigger the
production and deposition of A in the brain of BALB/c
mice. For the time being, however, the impact of this
remains unclear.
In conclusion, our data do not unequivocally support the
hypothesis that Cpn infection induces the formation of AD
like A plaques in the brain of BALB/c mice, as suggested
by Little et al. [19]. Accordingly, future studies are required
to investigate whether Cpn infections may aggravate AD
pathology by stimulating the formation of A plaques as
has been suggested in atherosclerosis, a disease that is also
characterized by pronounced local inXammation.
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